Stock DERM JOURNEY MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.33 USD -2.06% Intraday chart for Journey Medical Corporation -5.93% -42.19%
Mar. 21 Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024
Mar. 21 Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
AQ
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
AQ
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023
AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 vs. Solodyn
AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)
AQ
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations
AQ
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
AQ
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023
AQ
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
AQ
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
AQ
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
AQ
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DERM Stock
  4. News Journey Medical Corporation
  5. Press Releases